Honestly you need to learn more about nutrition before you try to post stuff. Stick to what you know which isn't much

That would be sweet. Let's take this $hit above .10 tomorrow and higher

Bro. My IQ is dropping by the second entertaining this idea that you really believe all this crap you are spitting out.

LMfao. Sodium 9%. That potato chip you are probably eating has a lot more.

So is too much alcohol, too much smoking, stress, red meat, etc.

210mg of sodium is NOTHING compared to other products.

Get a grip.

Dude your grasping at straws. Everything you eat has sodium. If you want to eat the entire can then go ahead.

Sheesh dude.

By the way, if you have any other questions about health and well being please let me know. I've been in healthcare for 22 years. I don't mind setting you straight.

And???????

Sodium is an ESSENTIAL electrolyte your body NEEDS in order to survive. Without it you will die from hyponatremia.

Lol omg. It's 9% of you daily value. Stick to what you know which no one here is really sure what you actually know.

9%. Lol.

TRTB will continue tomorrow $$$$$$

Lol yes that would be awesome!!! I think we are on a good track towards that

So mad bro!!!!

Yep totally agree. Nothing stoping this bad boy$$$$$

No I definitely attest that stocks do dip, settle out, form new bases etc. Higher lows is the name of the game. It's just funny watching him beg. I wish I had some dog treats to throw.

Great day here fellas. Looking forward to tomorrow$$$$$$$$$$

No. Don't change it. Admit that you were wrong.

Lol. It's hard to hear the truth!

Nope dead wrong as usual.

"Bet what? That it will close -5% to -18%. I ALREADY WON THIS ONE...its going to close between that range...then my 0.08 comes in few days"



So, being that it didn't close -5 to -18, we should follow you because why??????

A nice sincere apology to the entire board would be nice!

Lol post more post more!!!!

Lovin that big time$$$$$$$$$$!!

TRTB power hour has begun +233% low float $$$$$$$$

Can't see L2 do we have buys stacking

Ask slap!! Just bought 10k let's do this guys!!

Lol

Still not at .08.....are you packing yet???
Lol

I'd be rich as hell$$$$$

Lol damn I wish I dropped that much! Minus one 3 :)

ol yes I did mean 113,333 lol got too happy with the 3's key

TRTB $$$$$$ +400% dipping now

I'm in. 1133333 buy.

Are the mms on there f$&king with this?

Don't know if you noticed but we aren't going back to .08 lol

I've already got my cheapies from last week homey

Nice first post. You are obviously new. Float is locked.

By tomorrow this baby will be .20 easily

Aethlon Medical Discloses Expanded Access "Emergency Use" Pathway To Treat Ebola in the United States

http://finance.yahoo.com/news/aethlon-medical-discloses-expanded-access-121500294.html

SAN DIEGO, Nov. 19, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that it will provide Hemopurifier® therapy under FDA expanded access "emergency use" provisions to support requests from qualified physicians and institutes that may seek to treat ebola virus infection in the United States.

Aethlon previously disclosed that it would provide Hemopurifier® therapy on a humanitarian basis through FDA compassionate use access provisions, which allow for the use of an investigational device to treat an individual patient or small group based on clearance by FDA prior to treatment.

Based on FDA guidance, Aethlon will now provide Hemopurifier® therapy to treat Ebola infection through expanded access "emergency use" provisions in the United States. Expanded access "emergency use" of an investigational device does not require advance FDA approval for life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.

The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. In the treatment of Ebola, Aethlon recently announced that Hemopurifier® therapy was administered to Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients. At the time of treatment, which occurred at Frankfurt University Hospital in Germany, the patient was unconscious and suffering from multiple organ failure.

The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment. Since the administration of Hemopurifier® therapy, Frankfurt University Hospital officials have reported that the Ebola virus is no longer detectable in the patient's blood and full recovery is expected.

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

AEMD news dollarland baby

Aethlon Medical Discloses Expanded Access "Emergency Use" Pathway To Treat Ebola in the United States

http://finance.yahoo.com/news/aethlon-medical-discloses-expanded-access-121500294.html

SAN DIEGO, Nov. 19, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that it will provide Hemopurifier® therapy under FDA expanded access "emergency use" provisions to support requests from qualified physicians and institutes that may seek to treat ebola virus infection in the United States.

Aethlon previously disclosed that it would provide Hemopurifier® therapy on a humanitarian basis through FDA compassionate use access provisions, which allow for the use of an investigational device to treat an individual patient or small group based on clearance by FDA prior to treatment.

Based on FDA guidance, Aethlon will now provide Hemopurifier® therapy to treat Ebola infection through expanded access "emergency use" provisions in the United States. Expanded access "emergency use" of an investigational device does not require advance FDA approval for life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.

The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. In the treatment of Ebola, Aethlon recently announced that Hemopurifier® therapy was administered to Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients. At the time of treatment, which occurred at Frankfurt University Hospital in Germany, the patient was unconscious and suffering from multiple organ failure.

The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment. Since the administration of Hemopurifier® therapy, Frankfurt University Hospital officials have reported that the Ebola virus is no longer detectable in the patient's blood and full recovery is expected.

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

How was that close of -5 to 18%???

Wrong. Again.

Love the news!!!!!! Dollar land baby

AEMD NEWS. $$$$ headed to dollarland!!!!

Aethlon Medical Discloses Expanded Access "Emergency Use" Pathway To Treat Ebola in the United States

http://finance.yahoo.com/news/aethlon-medical-discloses-expanded-access-121500294.html

SAN DIEGO, Nov. 19, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that it will provide Hemopurifier® therapy under FDA expanded access "emergency use" provisions to support requests from qualified physicians and institutes that may seek to treat ebola virus infection in the United States.

Aethlon previously disclosed that it would provide Hemopurifier® therapy on a humanitarian basis through FDA compassionate use access provisions, which allow for the use of an investigational device to treat an individual patient or small group based on clearance by FDA prior to treatment.

Based on FDA guidance, Aethlon will now provide Hemopurifier® therapy to treat Ebola infection through expanded access "emergency use" provisions in the United States. Expanded access "emergency use" of an investigational device does not require advance FDA approval for life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.

The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. In the treatment of Ebola, Aethlon recently announced that Hemopurifier® therapy was administered to Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients. At the time of treatment, which occurred at Frankfurt University Hospital in Germany, the patient was unconscious and suffering from multiple organ failure.

The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment. Since the administration of Hemopurifier® therapy, Frankfurt University Hospital officials have reported that the Ebola virus is no longer detectable in the patient's blood and full recovery is expected.

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).